We are committed to build a world-leading Inhalation medicines company
Transpire Bio, a development-stage pharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, has today announced the addition of another senior-level inhalation expert to their leadership team, filling a key position.
Dr. Abhishek Gupta ‘Abhi’ will be assuming the role of Chief Scientific Officer (CSO) and interim Chief Corporate Development Officer for the company. As CSO, Dr. Gupta will provide leadership for all R&D activities, including the organic build-out of high-performing inhalation R&D teams in Miami, Florida and inorganic initiatives. Abhi has been working in R&D product development across various dosage forms for over 23 years, and over 20 of these years focused primarily on inhalation drug-device combination products. His time in industry has included leadership positions at Novartis Pharmaceuticals, Nektar Therapeutics, Cardinal Health, Lupin, and most recently, Cipla as the SVP & Head of R&D, North America.
“I am excited that Abhi has decided to join the Transpire Bio team,” said Dr. Xian-Ming Zeng, CEO of Transpire Bio. “Abhi has been instrumental in the successful development of several generic and branded inhalation products and has the leadership skills to drive the R&D projects to help meet the company’s objectives. I speak for the entire Transpire Bio leadership team in welcoming him to the group knowing that he will provide critical contributions in an outstanding manner.” Dr. Gupta commented “I’m excited to join the experienced and talented team at Transpire Bio. This team has had a very successful track record of bringing some of the world’s most complex and innovative products into the hands of the patients. I look forward to establishing and advancing our complex and innovative pipeline assets with urgency to address the unmet medical need for our patients, customers and global stakeholders”.
Transpire Bio Inc. is a US-based, development-stage biopharmaceutical company headquartered in Miami, Florida. The mission of Transpire Bio is to harness the power of inhaled drug delivery to improve patient access to important therapies and develop treatments for serious diseases where therapeutic options are significantly lacking. Transpire Bio develops multiple inhaled approaches, including metered-dose inhalers, soft-mist inhalers, and dry powder inhalers.
For more information, please visit www.transpirebio.com, info@transpirebio.com +1 954.908.2233